Background {#Sec1}
==========

The renin--angiotensin system (RAS) has been classically described as a circulating hormone system that regulates hydroelectrolytic balance and cardiovascular function \[[@CR1]\]. The better-known bioactive peptide of RAS, angiotensin II, is produced by the action of angiotensin-converting enzyme (ACE) and acts through AT1 receptors \[[@CR1]\]. The use of ACE inhibitors and AT1 receptor blockers is the universally recognized first-line strategy in the treatment of hypertension and cardiovascular disease \[[@CR2]\].

Over the past 25 years, the classic understanding of RAS has undergone an extensive revision \[[@CR3], [@CR4]\]. The activities of different angiotensin-converting peptidases have been shown to produce several angiotensins that counterbalance the action of Ang II \[[@CR1]\]. Further, several organs, tissues, and cells express all the components of RAS \[[@CR5]\]. These local and intracellular RAS can regulate long-term biologic processes such as cell growth, proliferation, and tissue repair \[[@CR1], [@CR4], [@CR5]\].

The newly expanded view of RAS describes endocrine, paracrine, autocrine, and intracrine functions and demonstrates that this peptidergic system regulates more diverse physiological phenomena than previously described \[[@CR1], [@CR4]\]. Moreover, the imbalance of RAS components has been associated with several chronic pathologies that go beyond cardiovascular and renal diseases \[[@CR6]\], including proliferative (such as cancer) \[[@CR7], [@CR8]\] and degenerative disorders of the central nervous system (such as Alzheimer's disease) \[[@CR9], [@CR10]\]. These diseases are primarily responsible for morbidity and mortality of adults in Western countries \[[@CR11]--[@CR13]\]. For this reason, there is great utility for RAS-modulating drugs and application of RAS components as diagnostic/prognostic biomarkers of chronic diseases \[[@CR4], [@CR7], [@CR9], [@CR14], [@CR15]\].

Experimental evidence suggests an important influence of gonadal hormones on RAS, which could explain, in part, sex differences in arterial pressure and in the onset of cardiovascular diseases \[[@CR3], [@CR16]\]. Studies in animal models have shown that the expression of angiotensin-converting enzymes is regulated by estrogens and testosterone in several tissues \[[@CR16]\]. These peptidases can be secreted to the extracellular space from several different tissues \[[@CR17]\], and gender differences are reflected in body fluids \[[@CR10]\]. Studies performed in children and young adults have described basal activity of ACE, as well as the maximum ACE inhibition after enalapril treatment, and found that they are significantly lower in women than in men, suggesting that estrogens and androgens could affect serum soluble ACE activity and lead to sexual differences in blood pressure \[[@CR18]\]. Therefore, sex differences should be considered in the study of RAS components and the search for new serum biomarkers.

Here, we describe the activity of five crucial angiotensin-regulating peptidases (ACE, ACE2, aminopeptidase A (APA), aminopeptidase N (APN), and neutral endopeptidase (NEP) \[[@CR1]\] in the serum of adult men and women. In our study, male and female individuals were described as good models of normal health and considered to be "control" subjects for chronic diseases. All participants were between 41 and 70 years old (typically, this is the age of onset of several cardiovascular and proliferative disorders and early stages of neurodegenerative diseases \[[@CR11]--[@CR13]\]), did not have any chronic pathology, and were not under any pharmacological treatment. Using this cohort, we sought to detect sex differences in RAS peptidase serum activity with aging.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Participants in this study comprised 118 healthy individuals with no history of any cardiovascular, proliferative, or central nervous system degenerative disease, ranging from 41--70 years old (60 males; age 56.58 ± 6.47 years; 58 females; age 54.47 ± 4.99 years). All participants underwent thorough medical examination, and we excluded all those who presented chronic pathologies involving drug treatment, such as estrogen replacement therapy, hormonal contraceptives or testosterone, or any significant neurologic, systemic, or psychiatric disorder that could cause cognitive impairment, as well as any who were pregnant or breastfeeding. All participants were informed of the extent of the study and signed an informed consent document approved by the Ethical and Scientific Committees (CEIC PGA-2).

Sample preparation {#Sec4}
------------------

Blood samples (10 mL) were collected by venipuncture into heparinized tubes after fasting overnight. Following centrifugation (1500 rpm, for 10 min), serum samples were separated and stored frozen at −80 °C until the analysis of renin--angiotensin system enzyme activity.

Renin--angiotensin system-regulating enzyme activity {#Sec5}
----------------------------------------------------

Enzyme activity in serum samples was measured by spectrofluorimetry in a microplate reader fluorometer FLUOstar OPTIMA (BMG Labtech). Angiotensin-converting enzyme (ACE/CD143: EC 3.4.11.1), angiotensin-converting enzyme 2 (ACE 2: EC 3.4.17.23), aminopeptidase A (APA/CD143: EC 3.4.11.7), aminopeptidase N (APN/CD13: EC 3.4.11.2), and neutral endopeptidase (NEP/CD10: EC 3.4.24.11) activity were measured. All samples were analyzed in triplicate and incubated at 37 ° C with their respective fluorogenic substrates in microplates for either 30 min (ACE, APA, APN, NEP/CD10) or 2 h (ACE2). Blanks were also included. The incubation times were based on preliminary assays to assess the linearity of the reaction over time as well as protein content. When introduced into the fluorimeter, specific emission and excitation filters for each substrate were selected. Each well was assayed with 10 flashes and the signals obtained were averaged. The value for the blank was discounted. The enzyme activity was expressed as units of enzyme activity per milliliter of serum (U/mL). One unit of activity is the amount of enzyme required to release 1 pmol of fluorescent product per minute. Specific inhibition assays for each substrate were performed to ensure appropriate measurement (86% or more inhibition accuracy was accepted).

### ACE activity assay {#Sec6}

Estimation of ACE activity was based on the fluorescence of the product generated upon hydrolysis by the enzyme of the substrate Abz-Gly-Phe(NO2) Pro (Bachem E2920). Fifty microliters of serum samples and 250 μL of substrate with 150 mM Tris-Hcl buffer, pH 8.3, plus 0.3 M NaCl were placed in a microplate reader and incubated as previously described. Excitation was at 355 nm and emission at 410 nm. The inhibition assay for ACE activity was performed with captopril (10 μM, Sigma).

### ACE2 activity assay {#Sec7}

The ACE2 activity assay was based on the fluorescence of the product generated upon hydrolysis by the enzyme of the substrate Abz-Ser-Pro-3-nitro-Tyr-OH (SPNPT; Bachem E2920). Reactions were initiated by adding 70 μL of the appropriate incubation mixture (substrate, 50 mM Tris-HCl buffer, pH 7.5, 2 μg BSA) to 30 μL of sample. After incubation, the fluorescence intensity was measured with an excitation filter at 355 nm and an emission filter at 410 nm. The inhibition assay for ACE2 activity was performed using DX600 (1 μM, Bachem).

### APA and APN/CD13 activity assay {#Sec8}

APA and APN/CD13 activity were measured using APA-β-naphthylamide as a substrate (Sigma N8381). Both were dissolved in 50 mM phosphate buffer. In the case of APA activity, 10 μL of serum were incubated with 190 μL of the mixture and 2 μg BSA, DTT, and CaCl2 were added to ensure that the reaction occurred. For APN activity, not only 2 μg of BSA but also the specific AlaAP inhibitor puromycin (40 μM) was added to discriminate between the AlaAP and APN/CD13 forms of total alanine aminopeptidase activity. Excitation was at 340 nm and emission at 410 nm. APA inhibition assay was performed using 1,10-phenanthroline (1,2 mM, Sigma) and APN/CD13 using leuhistin (0,05 mM, Sigma).

### NEP/CD10 activity assay {#Sec9}

The NEP/CD10 assay was performed by incubating 30-μL samples with 70 μL of a saturating concentration of N-dansyl-D-Ala-Gly-pNO2-Phe-Gly (DAGNPG, Sigma E39220). Captopril was added to discriminate between NEP activity and ACE forms. Excitation was at 340 nm and emission at 562 nm. NEP inhibition was performed using DL-thiorphan (Sigma).

Statistical analyses {#Sec10}
--------------------

To compare sexes, the female and male groups were each subdivided into two groups, separated by the median value of the sample. All reported values represent the median of the individual determination ± interquartile range (IQR). Statistical analysis was performed using SPSS® Statistics version 21. The Kolmogorov--Smirnov test was used to test the normality distribution of the data. A Mann--Whitney *U* test was performed to detect differences between the sexes, as well as between younger (\<55 years) and older (≥55 years) participants when variables showed a non-normal distribution.

Linear regression models using systolic and diastolic blood pressures as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influence, were applied. Additionally, a linear regression analysis between age and renin--angiotensin system-regulating enzyme activities in women and men was performed.

Results {#Sec11}
=======

Descriptive parameters of 128 participants (all of them meeting inclusion criteria) are provided in Table [1](#Tab1){ref-type="table"}. Men were found to have higher body mass indexes and higher blood pressure than women, as well as a lower body fat percentage. These differences were maintained among the specific age groups when a breakpoint of 55 years was selected to compare those less than or greater than 55 years of age (Table [2](#Tab2){ref-type="table"}). A lack of changes in these parameters was observed in men when comparing the under 55 group to those over 55 years and in women over 55, presented a tendency toward higher systolic blood pressure (*P* = 0.078) compared to women under 55 years (Table [3](#Tab3){ref-type="table"}).Table 1Descriptive statistics of the study populationWOMENMENMann--Whitney *U*MedianIQRNMedianIQRN*ZP* valueAge (years)54.976.345855.7610.1860−1.550.121BMI (kg/m^2^)23.454.155825.653.8360−3.51\<0.001Body fat (%)30.7011.955820.6110.5360−5.61\<0.001SBP (mmHg)120.521.558130.121.560−3.340.001DBP (mmHg)805.2558803.7560−2.570.010*Note*: *BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure Table 2Sex differences in BMI, body fat percentage, SBP, and DBP in younger (\<55 years) and older (≥55 years) participantsWOMENMENMann--Whitney *U*MedianIQRNMedianIQRN*ZP* value\< 55 yearsBMI (kg/m^2^)23.54.42825.44.531−2.3360.020Body fat (%)30.114.92820.21031−4.246\<0.001SBP (mmHg)12013281301931−2.7830.005DBP (mmHg)78.572880831−0.0050.047[\>]{.ul} 55 yearsBMI (kg/m^2^)23.353.83026.23.929−2.6640.008Body fat (%)31.159.63020.710.829−3.7350.000SBP (mmHg)12721301352329−1.8030.071DBP (mmHg)8053080029−1.6830.092*Note*: *BMI* body mass index, *SBP* systolic blood pressure, *DBP* diastolic blood pressure Table 3Effects of age (breakpoint [\>]{.ul}55 years) on BMI, body fat percentage, SBP, and DBP in all participants\< 55 years\> 55 yearsU Mann--WhitneyMedianIQRNMedianIQRN*ZP* valueWOMENBMI (kg/m^2^)23.54.42823.353.830−0.5370.591Body fat (%)30.114.92831.159.630−0.2650.791SBP (mmHg)12013281272130−17650.078DBP (mmHg)78.572880530−0.4590.646MENBMI (kg/m^2^)25.44.53126.23.929−0.0590.953Body fat (%)20.2103120.710.829−0.7920.429SBP (mmHg)13019311352329−12970.195DBP (mmHg)8083180029−0.1820.856*Note*: *BMI* Body mass index, *SBP* Systolic blood pressure, *DBP* diastolic blood pressure

ACE, ACE2, NEP, APN, and APA serum enzymatic activities were measured in men and women (Table [4](#Tab4){ref-type="table"}). Significantly lower serum APA activity levels were observed in men with respect to women; no changes were observed for ACE, ACE2, NEP, or APN.Table 4Renin--angiotensin system-regulating enzyme activities and sex differencesTOTALWOMENMENMann--Whitney *U*MedianIQRNMedianIQRNMedianIQR*NZP* valueACE783.3253.31118820.3253.3258771.3254.2760−1.2810.2ACE264.3321.5911864.6618.495863.1227.1460−0.3500.726NEP157021724.59118155941272.1258158461974.4460−1.0660.286APN102605417.8411810238599.258104364937.5960−0.7110.477APA41431296.7511843451225.79583946991.3560−2.1530.031*Note*: *ACE* angiotensin-converting enzyme, *ACE2* angiotensin-converting enzyme-2, *NEP* neutral endopeptidase, *APN* aminopeptidase N, *APA* aminopeptidase AValues are medians of peptidase activity recorded as pmol of units of peptidase (UP) per milliliter of serum

When we compared serum enzymatic activities separately in younger and older participants (breakpoint 55 years) (Table [5](#Tab5){ref-type="table"}), significantly lower ACE and APA serum activity levels were observed in men with respect to women, but without changes in ACE2, NEP, or AP. However, in the case of younger participants, significantly higher NEP serum enzymatic activity was observed in men than in women, but without changes in ACE, ACE2, APN, or APA. In contrast, in the case of older participants, significantly lower ACE and APA serum activity was observed in men than in women, but without changes in ACE2, NEP, or APN.Table 5Sex differences in ACE, ACE2, NEP, APN, and APA serum activities in younger (\<55 years) and older (≥ 55 years) participantsWOMENMENMann--Whitney *U*MedianIQRNMedianIQRN*ZP* value\< 55 yearsACE820.3249.7728841.4281.0231−0.7280.467ACE261.7116.692859.7523.5731−0.0320.975NEP154741187.5528162032030.3231−2.0170.044APN99315046.7428115176916.7531−1.6530.098APA43041225.792842811633.431−0.1210.903[\>]{.ul} 55 yearsACE815.9272.1330744.4201.4329−2.2920.022ACE271.1116.223070,0530.9229−0.3780.706NEP157031812.1530153441668.9329−0.5620.574APN102386688.673099734001.2329−0.5770.564APA43611240.15303820623.9729−2.7630.006*Note*: *ACE* angiotensin-converting enzyme, *ACE2* angiotensin-converting enzyme-2, *NEP* neutral endopeptidase, *APN* aminopeptidase N, *APA* aminopeptidase A

The effects of age, with a breakpoint of 55 years, on ACE, ACE2, NEP, APN, and APA serum activity was measured in all the participants, as well as separately in men and women (Table [6](#Tab6){ref-type="table"}). Significantly lower ACE and a trend toward lower APA (*P* = 0.063) serum enzymatic activity was detected in older men, but without changes in ACE2, NEP, or APN. In women, significantly higher ACE2 serum activity was observed in older women, but with no changes in ACE, NEP, APN, or APA. To evaluate the statistical association between age and serum aminopeptidase activities, linear regression models were applied separately in women and men (Table [7](#Tab7){ref-type="table"}). These analyses indicated a positive association between ACE2 serum activity and age in women. Accordingly, a linear regression model using systolic and diastolic blood pressure as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influence, showed that age, sex, and ACE2 influence systolic blood pressure, while only sex influences diastolic blood pressure, across the continuum of age (Table [8](#Tab8){ref-type="table"}).Table 6Effects of age (breakpoint [\>]{.ul}55 years) on ACE, ACE2, NEP, APN, and APA serum activities in women and men\<55 years≥ 55 yearsMann--Whitney *U*MedianIQRNMedianIQRN*ZP* valueWOMENACE820.3249.7728815.9272.1330−0.7310.465ACE261.7116.692871.1116.2230−2.1690.030NEP154741187.5528157031812.1530−0.9650.335APN99315046.7428102386688.6730−0.7470.455APA43041225.792843611240.1530−0.3270.744MENACE841.4281.0231744.4201.4329−1.9600.049ACE259.7523.573170.0530.9229−1.0070.313NEP162032030.3231153441668.9329−1.0130.311APN115176916.753199734001.2329−1.6200.105APA42811633.4313820623.9729−1.8560.063*Note*: *ACE* angiotensin-converting enzyme, *ACE2* angiotensin-converting enzyme-2, *NEP* neutral endopeptidase, *APN* aminopeptidase N, *APA* aminopeptidase A Table 7Linear regression anaysis between age and renin--angiotensin system-regulating enzyme activities in women and men*B* (95% CI)β*R* ^2^*P* valueACEWomen5.979 (−5.408, 17.365)0.1390.0190.297Men−6.139 (−14.206, 1.927)−0.1960.0380.133ACE2Women0.959 (0.323, 1.595)0.380.1450.004Men0.664 (−0.193, 1.521)0.2050.0420.126NEPWomen14.87 (−48.08, 77.82)0.0630.0040.638Men−52.80 (−105.2, −0.402)−0.2560.0660.048APNWomen162.9 (−68.22, 394.1)0.1850.0340.163Men−116.4 (−266.7, 33.78)−0.20.0400.126APAWomen51.75 (−16.21, 119.7)0.20.0400.133Men−29.23 (−72.52, 14.06)−0.1750.0310.182*Note*: ACE angiotensin-converting enzyme, *ACE2* angiotensin-converting enzyme-2, *NEP* neutral endopeptidase, *APN* aminopeptidase N, *APA* aminopeptidase A Table 8Linear regression models including systolic blood pressure and diastolic blood pressure as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influenceDependent variablesPredictorsB (95% CI)βR^2^Adjusted *R* ^2^SEE*P* valueSBPModel0.4780.22815.263\<0.001Age (years)110.54 (47.06, 174.03)0.3040.001Sex−7.22 (−13.02,−1.43)−0.2210.015ACE227.99 (3.19, 82.78)0.1940.027Constant−101.9 (−212.9, 9.22)0.071DBPModel0.2250.0516.685\<0.001Sex−3.06 (−5.55,−0.57)−0.2210.015Constant84.71 (80.78, 88.64)\<0.001*Note*: *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *ACE2* angiotensin-converting enzyme-2

Discussion {#Sec12}
==========

Our results revealed sex differences in RAS serum enzymatic activities. Sex differences in soluble aminopeptidases, such as APA, have been described by other authors \[[@CR19]\]. Moreover, it has been suggested that sex differences in blood pressure could be due to the effects of sex hormones on some of these peptidases, which are critical for the regulation of RAS \[[@CR20]\]. In the present work, a critical range of age was selected for the inclusion of participants, all of whom were healthy middle-aged individuals, thus leading to a methodological improvement with respect to previous studies on this topic.

It has been proposed that sex differences in the regulation of arterial pressure by RAS could be due in part to a decrease in ACE serum activity in males, contrasting with a predominant ACE2 activity in females that could be lost in the post-menopausal period \[[@CR16]\]. Sex differences in the incidence and evolution of cardiovascular disease and hypertension are also suggested to be due to the differential effects of sex steroids on critical components of RAS, which could possibly explain sex differences in blood pressure levels \[[@CR21]\].

To detect specific physiological sex differences in the serum activities of RAS peptidases, we selected participants ranging from 41 to 70 years old, representing a period of time in which the onset of several cardiovascular and proliferative disorders and early stages of neurodegenerative diseases is most prevalent \[[@CR11]--[@CR13]\], who did not have any chronic pathology, and were not under any pharmacological treatment. Consequently, this sample was intended to constitute a specific ideal model, to avoid bias caused by concomitant pathologies and/or medications.

Estrogen decrease, whereas testosterone increases, ACE activity, and consequently Ang II levels \[[@CR20]\]. Accordingly, in our study, men aged ≥55 years showed a significantly lower ACE activity with respect to women. Further, among men, a significant reduction in ACE activity was observed in older participants ([\>]{.ul}55 years), with respect to younger ones (\<55 years). These results suggest a greater influence on ACE activity by testosterone, compared to estrogens.

Post-menopausal changes in estrogen levels are well known \[[@CR22]\], as a consequence of the physiological decline in ovarian follicle numbers \[[@CR23]\], leading to sleep and body temperature disturbances in older women \[[@CR24]\]. Although andropausia has been described as a controversial concept \[[@CR25]\], it has been suggested that androgen deficiency in older men has been overlooked in clinical settings \[[@CR26]\]. In 2006, the Massachusetts Male Aging Study (MMAS) described a reduction in testosterone levels in 21% of men aged 55--59 years, 26% of those aged 60--69 years, and 31% of those aged 70--86 years \[[@CR27]\]. In fact, late-onset hypogonadism (age-related testosterone deficiency) has been recently recognized as a clinical syndrome associated with low testosterone levels and alteration of health status \[[@CR28], [@CR29]\], and the possibility that subclinical hypogonadism in andropausal men could be a physiologic response of the hypothalamus has been proposed \[[@CR30]\]. The breakpoint of 55 years selected for comparisons between groups of age in our study is relevant to these findings.

Pre-menopausal women have lower blood pressure with respect to post-menopausal women \[[@CR31]\] and pre-andropausal men \[[@CR32]\], indicating that a difference in cardiovascular risk could be mediated by RAS. In fact, androgens can stimulate RAS \[[@CR33]\], and the sexually dimorphic pattern of hypertension in the spontaneously hypertensive rat is androgen-dependent, rather than estrogen-dependent \[[@CR34]\]. Accordingly, serum peptidases, such as ACE, ACE2, NEP, APN, and APA, which are important elements of the RAS, were studied here because dysregulation of these enzymes has been associated with hypertension and cardiovascular risk \[[@CR35]\]. Our results revealed sexual differences in these activities, with a different pattern in pre- and post-andropausal/post-menopausal subjects.

Sex differences in APA activity were observed in the selected subjects. More precisely, a significantly lower serum activity of this enzyme was found in men than in women. These results suggest lower production of angiotensin III in men, which exerts an important physiological regulatory action on cerebral circulation \[[@CR36]\]. However, a different pattern of sexual differences was observed in participants ≥55 years of age. In this group, significantly lower APA and ACE serum activities were observed in men compared to women. Considering that angiotensin III promotes increased blood pressure when injected intracerebroventricularly \[[@CR37]\], and taking into account that it has been reported that inhibitors of APA, the enzyme that produces angiotensin III, can act as antihypertensive drugs \[[@CR38], [@CR39]\]; these results could help explain the smaller changes in blood pressure usually observed in post-andropausal men, with respect to that observed in post-menopausal women.

The reduction in APA activity may be linked to a decrease in the production of angiotensin III, leading to a reduction in cerebral vasoconstriction. This could prevent the elevation of cerebral blood pressure, thus contributing to the decrease in cerebrovascular risk found in post-andropausal men compared to post-menopausal women. However, in participants \<55 years old, although significantly higher NEP and APN serum activities were observed, a lack of changes in ACE, ACE2, and APA serum activities was observed in men, with respect to women. Notably, reduced APA could be linked to higher levels of angiotensin II, thus tending to increase blood pressure. Further, elevated NEP in younger men could increase angiotensin 1-7, reducing this parameter.

With respect to aging, these serum enzymatic activities presented sex differences in the activity patterns when it was observed between younger (\<55 years) and older (≥55 years) participants. Thus, higher ACE2 activity was found in older women, whereas lower ACE and APA activities were observed in older men. Due to the fact that ACE2 activity can increase production of angiotensin 1-7, which leads to vasodilatatory, antiproliferative, and antifibrotic effects \[[@CR40]\], and considering that antithrombotic effects have been recently proposed for the ACE2-angiotensin (1-7)-Mas receptor axis \[[@CR41]\], the increase in ACE2 activity in the post-menopausal period in women could lead to a differential cardiovascular risk in men and women \[[@CR42]\].

Although post-menopausal women are known to have an increased cardiovascular risk, this fact does not necessary contradict the beneficial cardiovascular effects of the increase in ACE2 activity in older women. Thus, it cannot be discarded that the ACE2-ang1-7-Mas axis could counterbalance negative cardiovascular effects of other age-related mechanisms. Further studies are needed to detect angiotensin peptide changes induced by aging in both sexes.

A limitation of the study could be that we lack data regarding alcohol consumption, cigarette smoking status, or physical activity habits, additional information that could influence RAS activity. However, we must emphasize that in meeting our inclusion criteria, the participants did not have any chronic pathology and were not under any pharmacological treatment, making this a reasonably good sample for this study.

Conclusions {#Sec13}
===========

These results highlight sex differences in the aging pattern of renin--angiotensin system serum peptidases, suggesting a differential effect of aging in men, especially with respect to the breakpoint of andropausia, on the critical serum enzymatic activities of the RAS, which could correlate with sexual differences in cardiovascular risk.
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